

		EMLc	Codes ATC: L04AB04
Indication	Crohn disease site	Code ICD11: DD70.Z	
INN	Adalimumab		
Type de médicament	Biological agent		
Type de liste	Liste complémentaire (EML) (EMLc)		
Additional notes	EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.		
Formulations	Parenteral > General injections > SC: 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)		
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) Modifié en 2023 (TRS 1049)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	certolizumab pegol (Codes ATC: L04AB05) etanercept (Codes ATC: L04AB01) golimumab (Codes ATC: L04AB06) infliximab (Codes ATC: L04AB02)		
Renseignements sur le brevet	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org  Lire la suite sur les brevets. 		
Balises	Biological		
Wikipédia	Adalimumab 		
DrugBank	Adalimumab 		

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.

